Other formats:
BibTeX
LaTeX
RIS
@article{1455180,
author = {Toth, Gabor G. and De Bruyne, Bernard and Kala, Petr and Ribichini, Flavio L. and Casselman, Filip and Ramos, Ruben and Piroth, Zsolt and Fournier, Stephane and Van Mieghem, Carlos and Penicka, Martin and Mates, Martin and Van Praet, Frank and Degriek, Ivan and Barbato, Emanuele},
article_location = {New York},
article_number = {4},
doi = {http://dx.doi.org/10.1007/s12265-018-9818-9},
keywords = {Coronary artery bypass graft surgery; Fractional flow reserve; Coronary angiography; Graft patency},
language = {eng},
issn = {1937-5387},
journal = {Journal of Cardiovascular Translational Research},
title = {Study Design of the Graft Patency After FFR-Guided Versus Angiography-Guided CABG Trial (GRAFFITI)},
volume = {11},
year = {2018}
}
TY - JOUR
ID - 1455180
AU - Toth, Gabor G. - De Bruyne, Bernard - Kala, Petr - Ribichini, Flavio L. - Casselman, Filip - Ramos, Ruben - Piroth, Zsolt - Fournier, Stephane - Van Mieghem, Carlos - Penicka, Martin - Mates, Martin - Van Praet, Frank - Degriek, Ivan - Barbato, Emanuele
PY - 2018
TI - Study Design of the Graft Patency After FFR-Guided Versus Angiography-Guided CABG Trial (GRAFFITI)
JF - Journal of Cardiovascular Translational Research
VL - 11
IS - 4
SP - 269-273
EP - 269-273
PB - Springer
SN - 19375387
KW - Coronary artery bypass graft surgery
KW - Fractional flow reserve
KW - Coronary angiography
KW - Graft patency
N2 - Clinical benefit of invasive functionally guided revascularization has been mostly investigated and proven for percutaneous coronary intervention. It has never been prospectively evaluated whether a systematic fractional flow reserve (FFR) assessment is also beneficial in guiding coronary artery bypass graft surgery (CABG). The objective of the GRAft patency after FFR-guided versus angiography-guIded CABG (GRAFFITI) trial was to compare an FFR-guided revascularization strategy to the traditional angiography-guided revascularization strategy for patients undergoing CABG. Patients were enrolled with significantly diseased left anterior descending or left main stem and at least one major coronary artery with angiographically intermediate stenosis (30-90% diameter stenosis) that was assessed by FFR. Thereafter, while the FFR values were kept concealed, cardiac surgeons decided their intended procedural strategy based on the coronary angiography alone. At this point, patients underwent 1:1 randomization to either an FFR-guided or an angiography-guided CABG strategy. In case the patient was randomized to angiography-guided arm, cardiac surgeons kept their intended procedural strategy, i.e., CABG was guided solely on the basis of the coronary angiography. In case the patient was randomized to the FFR-guided arm, FFR values were disclosed to the surgeons who revised the surgical protocol according to the functional significance of each coronary stenosis. The primary endpoint of the trial was the rate of graft occlusion at 12 months, assessed by coronary computed tomography or coronary angiography. The secondary endpoints were (1) length of postoperative hospital stay; (2) changes in surgical strategy depending upon FFR results (in FFR-guided group only); and (3) rate of major adverse cardiac and cerebrovascular events, i.e., composite of death, myocardial infarction, stroke, and any revascularization during the follow-up period. This study is the first prospective randomized trial investigating potential clinical benefits, associated with FFR-guided surgical revascularization. Trial registration: NCT01810224.
ER -
TOTH, Gabor G., Bernard DE BRUYNE, Petr KALA, Flavio L. RIBICHINI, Filip CASSELMAN, Ruben RAMOS, Zsolt PIROTH, Stephane FOURNIER, Carlos VAN MIEGHEM, Martin PENICKA, Martin MATES, Frank VAN PRAET, Ivan DEGRIEK and Emanuele BARBATO. Study Design of the Graft Patency After FFR-Guided Versus Angiography-Guided CABG Trial (GRAFFITI). \textit{Journal of Cardiovascular Translational Research}. New York: Springer, 2018, vol.~11, No~4, p.~269-273. ISSN~1937-5387. Available from: https://dx.doi.org/10.1007/s12265-018-9818-9.
|
